181 related articles for article (PubMed ID: 35381971)
1. Clinical Utility of Implementing a Frontline NGS-Based DNA and RNA Fusion Panel Test for Patients with Suspected Myeloid Malignancies.
Bhai P; Hsia CC; Schenkel LC; Hedley BD; Levy MA; Kerkhof J; Santos S; Stuart A; Lin H; Broadbent R; Nan S; Yang P; Xenocostas A; Chin-Yee I; Sadikovic B
Mol Diagn Ther; 2022 May; 26(3):333-343. PubMed ID: 35381971
[TBL] [Abstract][Full Text] [Related]
2. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
[TBL] [Abstract][Full Text] [Related]
3. Validation, Implementation, and Clinical Impact of the Oncomine Myeloid Targeted-Amplicon DNA and RNA Ion Semiconductor Sequencing Assay.
Ferrone CK; Wong H; Semenuk L; Werunga B; Snetsinger B; Zhang X; Zhang G; Lui J; Richard-Carpentier G; Crocker S; Good D; Hay AE; Quest G; Carson N; Feilotter HE; Rauh MJ
J Mol Diagn; 2021 Oct; 23(10):1292-1305. PubMed ID: 34365012
[TBL] [Abstract][Full Text] [Related]
4. Clinical Utility of Targeted Next-Generation Sequencing Assay to Detect Copy Number Variants Associated with Myelodysplastic Syndrome in Myeloid Malignancies.
Jiang L; Pallavajjala A; Huang J; Haley L; Morsberger L; Stinnett V; Hardy M; Park R; Ament C; Finch A; Shane A; Parish R; Nozari A; Long P; Adams E; Smith K; Parimi V; Dougaparsad S; Long L; Gocke CD; Zou YS
J Mol Diagn; 2021 Apr; 23(4):467-483. PubMed ID: 33577993
[TBL] [Abstract][Full Text] [Related]
5. Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasms.
Rosenthal SH; Gerasimova A; Ma C; Li HR; Grupe A; Chong H; Acab A; Smolgovsky A; Owen R; Elzinga C; Chen R; Sugganth D; Freitas T; Graham J; Champion K; Bhattacharya A; Racke F; Lacbawan F
PLoS One; 2021; 16(4):e0243683. PubMed ID: 33909614
[TBL] [Abstract][Full Text] [Related]
6. Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use.
Bacher U; Shumilov E; Flach J; Porret N; Joncourt R; Wiedemann G; Fiedler M; Novak U; Amstutz U; Pabst T
Blood Cancer J; 2018 Nov; 8(11):113. PubMed ID: 30420667
[TBL] [Abstract][Full Text] [Related]
7. Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome.
Hughes CFM; Gallipoli P; Agarwal R
Pathology; 2021 Apr; 53(3):328-338. PubMed ID: 33676768
[TBL] [Abstract][Full Text] [Related]
8. Molecular findings in myeloid neoplasms.
Tran TB; Siddon AJ
Int J Lab Hematol; 2023 Aug; 45(4):442-448. PubMed ID: 37345257
[TBL] [Abstract][Full Text] [Related]
9. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
10. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
Duncavage EJ; Tandon B
Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
[TBL] [Abstract][Full Text] [Related]
11. Clinical characterization of the mutational landscape of 24,639 real-world samples from patients with myeloid malignancies.
Hogg G; Severson EA; Cai L; Hoffmann HM; Holden KA; Fitzgerald K; Kenyon A; Zeng Q; Mooney M; Gardner S; Chen W; Nagan N; Boles D; Parker S; Richman TJ; Letovsky S; Dong H; Anderson SM; Ramkissoon S; Reddy P; Eisenberg M; Chenn A; Jensen TJ
Cancer Genet; 2023 Nov; 278-279():38-49. PubMed ID: 37586297
[TBL] [Abstract][Full Text] [Related]
12. [Significance of Targeted Sequencing Assay for Patients with Suspected Myeloid Malignancies].
Zhang LJ; Shi YY; Chen Y; Deng Y; Ding YH; Li Z; Chen KK; Ding BH; Wang CL; Yu L; He ZM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1985-1990. PubMed ID: 33283730
[TBL] [Abstract][Full Text] [Related]
13. Analytical Validation of a 37-Gene Next-Generation Sequencing Panel for Myeloid Malignancies and Review of Initial Findings Incorporating Updated 2022 Diagnostic and Prognostic Guidelines.
Leung B; Aung H; Nandini A; Abdulrasool G; Lau C; Seymour L
J Mol Diagn; 2024 May; 26(5):399-412. PubMed ID: 38367765
[TBL] [Abstract][Full Text] [Related]
14. Clinical Validation of a Myeloid Next-Generation Sequencing Panel for Single-Nucleotide Variants, Insertions/Deletions, and Fusion Genes.
Izevbaye I; Liang LY; Mather C; El-Hallani S; Maglantay R; Saini L
J Mol Diagn; 2020 Feb; 22(2):208-219. PubMed ID: 31751678
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study.
Vantyghem S; Peterlin P; Thépot S; Ménard A; Dubruille V; Debord C; Guillaume T; Garnier A; Le Bourgeois A; Wuilleme S; Godon C; Theisen O; Eveillard M; Delaunay J; Maisonneuve H; Morineau N; Villemagne B; Vigouroux S; Subiger F; Lestang E; Loirat M; Parcelier A; Godmer P; Mercier M; Trebouet A; Luque Paz D; Le Calloch R; Le Clech L; Bossard C; Moreau A; Ugo V; Hunault M; Moreau P; Le Gouill S; Chevallier P; Béné MC; Le Bris Y
Haematologica; 2021 Mar; 106(3):701-707. PubMed ID: 32241844
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms.
Patel U; Luthra R; Medeiros LJ; Patel KP
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S62-S74. PubMed ID: 28760304
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of next-generation sequencing compared to cytogenetics in patients with suspected myelodysplastic syndrome.
Kawata E; Lazo-Langner A; Xenocostas A; Hsia CC; Howson-Jan K; Deotare U; Saini L; Yang P; Broadbent R; Levy M; Howlett C; Stuart A; Kerkhof J; Santos S; Lin H; Sadikovic B; Chin-Yee I
Br J Haematol; 2021 Feb; 192(4):729-736. PubMed ID: 32588428
[TBL] [Abstract][Full Text] [Related]
18. Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing.
Kohlmann A; Bacher U; Schnittger S; Haferlach T
Leuk Lymphoma; 2014 Aug; 55(8):1725-34. PubMed ID: 24144312
[TBL] [Abstract][Full Text] [Related]
19. Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms.
Kanagal-Shamanna R; Hodge JC; Tucker T; Shetty S; Yenamandra A; Dixon-McIver A; Bryke C; Huxley E; Lennon PA; Raca G; Xu X; Jeffries S; Quintero-Rivera F; Greipp PT; Slovak ML; Iqbal MA; Fang M
Cancer Genet; 2018 Dec; 228-229():197-217. PubMed ID: 30377088
[TBL] [Abstract][Full Text] [Related]
20. Detection of recurrent, rare, and novel gene fusions in patients with acute leukemia using next-generation sequencing approaches.
Kim B; Kim E; Lee ST; Cheong JW; Lyu CJ; Min YH; Choi JR
Hematol Oncol; 2020 Feb; 38(1):82-88. PubMed ID: 31875988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
